A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/2
168
about 3.3 years
18+
4 sites in TX, VA
What this study is about
Researchers are testing the safety and effectiveness of OR502, a monoclonal antibody, alone or with cemiplimab, in people with advanced solid tumors. The trial will last for about 1 year and involve approximately 168 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cemiplimab
- 2.Take OR502
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cemiplimab
Primary: Adverse Events and Serious Adverse Events, Dose-limiting Toxicity
Secondary: Disease Control Rate (DCR), Objective Response Rate (ORR), Pharmacokinetics of OR502, Progression Free Survival (PFS)
Oncology